CD19 and acute lymphoblastic leukemia: Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has provided an additional option for B-ALL and other B-cell malignancies (6, 7, 8), yet relapse remains a significant challenge, occurring in 30 to 60% of the cases (9, 10).